



1/27

**FIG. 1****FIG. 2**




FIG. 3





FIG. 4A

4/27

**FIG. 4B**

5/27




FIG. 5

6/27

ACU-4429 Phase 1a: Rod ERG Suppression (24h)






FIG. 6


7/27

**FIG. 7**


8/27

**FIG. 8**



9/27

**FIG. 9**



10/27

**FIG. 10**


11/27

**FIG. 11A****FIG. 11B**


12/27

Metabolite Radioprofiles at 4 Hours Post-dose on Day 7**FIG. 12A****FIG. 12B**

13/27

**FIG. 13**

14/27

**FIG. 14**




FIG. 15




FIG. 16A

17/27




FIG. 16B






FIG. 16C


18/27


**FIG. 16D**

19/27


**FIG. 16E**


20/27

**FIG. 16F**

**FIG. 17**

22/27

**FIG. 18**

**FIG. 19**




FIG. 20

Comparison of ONL






FIG. 21

26/27

**FIG. 22**

27/27

WIS-11-04**FIG. 23**